The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Non-alcoholic Steatohepatitis-Global Market Insights and Sales Trends 2024
Synopsis
Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.
The global Non-alcoholic Steatohepatitis market size is expected to reach US$ 9500.6 million by 2029, growing at a CAGR of 20.6% from 2023 to 2029. The market is mainly driven by the significant applications of Non-alcoholic Steatohepatitis in various end use industries. The expanding demands from the Oral and Parenteral, are propelling Non-alcoholic Steatohepatitis market. Solid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Liquid segment is estimated at % CAGR for the next seven-year period.
NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and liver cell damage, typically occurring in individuals who do not consume excessive alcohol. Several factors are driving the growth of the NASH market. Firstly, the rising prevalence of obesity and metabolic disorders, such as diabetes and dyslipidemia, is contributing to the increasing incidence of NASH. Unhealthy lifestyles, sedentary habits, and poor dietary choices are leading to a higher risk of developing NASH, creating a substantial patient population in need of diagnosis and treatment. Secondly, the improved understanding and awareness of NASH among healthcare professionals and the general population have resulted in increased diagnosis rates. As the medical community recognizes the long-term complications and progression of NASH, there is a greater emphasis on identifying patients with NASH and implementing appropriate management strategies.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-alcoholic Steatohepatitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-alcoholic Steatohepatitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-alcoholic Steatohepatitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-alcoholic Steatohepatitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-alcoholic Steatohepatitis covered in this report include AstraZeneca, Pfizer, GSK, Novo Nordisk, Roche, AbbVie, Galectin Therapeutics, Galmed Pharmaceuticals and Gilead, etc.
The global Non-alcoholic Steatohepatitis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Pfizer
GSK
Novo Nordisk
Roche
AbbVie
Galectin Therapeutics
Galmed Pharmaceuticals
Gilead
Intercept pharma
Non-alcoholic Steatohepatitis
Takeda
Global Non-alcoholic Steatohepatitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-alcoholic Steatohepatitis market, Segment by Type:
Solid
Liquid
Global Non-alcoholic Steatohepatitis market, by Application
Oral
Parenteral
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-alcoholic Steatohepatitis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.
The global Non-alcoholic Steatohepatitis market size is expected to reach US$ 9500.6 million by 2029, growing at a CAGR of 20.6% from 2023 to 2029. The market is mainly driven by the significant applications of Non-alcoholic Steatohepatitis in various end use industries. The expanding demands from the Oral and Parenteral, are propelling Non-alcoholic Steatohepatitis market. Solid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Liquid segment is estimated at % CAGR for the next seven-year period.
NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and liver cell damage, typically occurring in individuals who do not consume excessive alcohol. Several factors are driving the growth of the NASH market. Firstly, the rising prevalence of obesity and metabolic disorders, such as diabetes and dyslipidemia, is contributing to the increasing incidence of NASH. Unhealthy lifestyles, sedentary habits, and poor dietary choices are leading to a higher risk of developing NASH, creating a substantial patient population in need of diagnosis and treatment. Secondly, the improved understanding and awareness of NASH among healthcare professionals and the general population have resulted in increased diagnosis rates. As the medical community recognizes the long-term complications and progression of NASH, there is a greater emphasis on identifying patients with NASH and implementing appropriate management strategies.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-alcoholic Steatohepatitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-alcoholic Steatohepatitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-alcoholic Steatohepatitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-alcoholic Steatohepatitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-alcoholic Steatohepatitis covered in this report include AstraZeneca, Pfizer, GSK, Novo Nordisk, Roche, AbbVie, Galectin Therapeutics, Galmed Pharmaceuticals and Gilead, etc.
The global Non-alcoholic Steatohepatitis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Pfizer
GSK
Novo Nordisk
Roche
AbbVie
Galectin Therapeutics
Galmed Pharmaceuticals
Gilead
Intercept pharma
Non-alcoholic Steatohepatitis
Takeda
Global Non-alcoholic Steatohepatitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-alcoholic Steatohepatitis market, Segment by Type:
Solid
Liquid
Global Non-alcoholic Steatohepatitis market, by Application
Oral
Parenteral
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-alcoholic Steatohepatitis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Non-alcoholic Steatohepatitis
1.1 Non-alcoholic Steatohepatitis Market Overview
1.1.1 Non-alcoholic Steatohepatitis Product Scope
1.1.2 Non-alcoholic Steatohepatitis Market Status and Outlook
1.2 Global Non-alcoholic Steatohepatitis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Non-alcoholic Steatohepatitis Market Size by Region (2018-2029)
1.4 Global Non-alcoholic Steatohepatitis Historic Market Size by Region (2018-2023)
1.5 Global Non-alcoholic Steatohepatitis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Non-alcoholic Steatohepatitis Market Size (2018-2029)
1.6.1 North America Non-alcoholic Steatohepatitis Market Size (2018-2029)
1.6.2 Europe Non-alcoholic Steatohepatitis Market Size (2018-2029)
1.6.3 Asia-Pacific Non-alcoholic Steatohepatitis Market Size (2018-2029)
1.6.4 Latin America Non-alcoholic Steatohepatitis Market Size (2018-2029)
1.6.5 Middle East & Africa Non-alcoholic Steatohepatitis Market Size (2018-2029)
2 Non-alcoholic Steatohepatitis Market by Type
2.1 Introduction
2.1.1 Solid
2.1.2 Liquid
2.2 Global Non-alcoholic Steatohepatitis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Non-alcoholic Steatohepatitis Historic Market Size by Type (2018-2023)
2.2.2 Global Non-alcoholic Steatohepatitis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Non-alcoholic Steatohepatitis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Non-alcoholic Steatohepatitis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Non-alcoholic Steatohepatitis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Non-alcoholic Steatohepatitis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Non-alcoholic Steatohepatitis Revenue Breakdown by Type (2018-2029)
3 Non-alcoholic Steatohepatitis Market Overview by Application
3.1 Introduction
3.1.1 Oral
3.1.2 Parenteral
3.2 Global Non-alcoholic Steatohepatitis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Non-alcoholic Steatohepatitis Historic Market Size by Application (2018-2023)
3.2.2 Global Non-alcoholic Steatohepatitis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Non-alcoholic Steatohepatitis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Non-alcoholic Steatohepatitis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Non-alcoholic Steatohepatitis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Non-alcoholic Steatohepatitis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Non-alcoholic Steatohepatitis Revenue Breakdown by Application (2018-2029)
4 Non-alcoholic Steatohepatitis Competition Analysis by Players
4.1 Global Non-alcoholic Steatohepatitis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-alcoholic Steatohepatitis as of 2022)
4.3 Date of Key Players Enter into Non-alcoholic Steatohepatitis Market
4.4 Global Top Players Non-alcoholic Steatohepatitis Headquarters and Area Served
4.5 Key Players Non-alcoholic Steatohepatitis Product Solution and Service
4.6 Competitive Status
4.6.1 Non-alcoholic Steatohepatitis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Non-alcoholic Steatohepatitis Products, Services and Solutions
5.1.4 AstraZeneca Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Non-alcoholic Steatohepatitis Products, Services and Solutions
5.2.4 Pfizer Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 GSK
5.3.1 GSK Profile
5.3.2 GSK Main Business
5.3.3 GSK Non-alcoholic Steatohepatitis Products, Services and Solutions
5.3.4 GSK Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.3.5 Novo Nordisk Recent Developments
5.4 Novo Nordisk
5.4.1 Novo Nordisk Profile
5.4.2 Novo Nordisk Main Business
5.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Products, Services and Solutions
5.4.4 Novo Nordisk Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.4.5 Novo Nordisk Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Non-alcoholic Steatohepatitis Products, Services and Solutions
5.5.4 Roche Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 AbbVie
5.6.1 AbbVie Profile
5.6.2 AbbVie Main Business
5.6.3 AbbVie Non-alcoholic Steatohepatitis Products, Services and Solutions
5.6.4 AbbVie Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.6.5 AbbVie Recent Developments
5.7 Galectin Therapeutics
5.7.1 Galectin Therapeutics Profile
5.7.2 Galectin Therapeutics Main Business
5.7.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Products, Services and Solutions
5.7.4 Galectin Therapeutics Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.7.5 Galectin Therapeutics Recent Developments
5.8 Galmed Pharmaceuticals
5.8.1 Galmed Pharmaceuticals Profile
5.8.2 Galmed Pharmaceuticals Main Business
5.8.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Products, Services and Solutions
5.8.4 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.8.5 Galmed Pharmaceuticals Recent Developments
5.9 Gilead
5.9.1 Gilead Profile
5.9.2 Gilead Main Business
5.9.3 Gilead Non-alcoholic Steatohepatitis Products, Services and Solutions
5.9.4 Gilead Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.9.5 Gilead Recent Developments
5.10 Intercept pharma
5.10.1 Intercept pharma Profile
5.10.2 Intercept pharma Main Business
5.10.3 Intercept pharma Non-alcoholic Steatohepatitis Products, Services and Solutions
5.10.4 Intercept pharma Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.10.5 Intercept pharma Recent Developments
5.11 Non-alcoholic Steatohepatitis
5.11.1 Non-alcoholic Steatohepatitis Profile
5.11.2 Non-alcoholic Steatohepatitis Main Business
5.11.3 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Products, Services and Solutions
5.11.4 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.11.5 Non-alcoholic Steatohepatitis Recent Developments
5.12 Takeda
5.12.1 Takeda Profile
5.12.2 Takeda Main Business
5.12.3 Takeda Non-alcoholic Steatohepatitis Products, Services and Solutions
5.12.4 Takeda Non-alcoholic Steatohepatitis Revenue (US$ Million) & (2018-2023)
5.12.5 Takeda Recent Developments
6 North America
6.1 North America Non-alcoholic Steatohepatitis Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Non-alcoholic Steatohepatitis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-alcoholic Steatohepatitis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-alcoholic Steatohepatitis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-alcoholic Steatohepatitis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-alcoholic Steatohepatitis Market Dynamics
11.1 Non-alcoholic Steatohepatitis Industry Trends
11.2 Non-alcoholic Steatohepatitis Market Drivers
11.3 Non-alcoholic Steatohepatitis Market Challenges
11.4 Non-alcoholic Steatohepatitis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
